

Introduction to Meningococcal Session

Jamie Loehr, MD

Advisory Committee on Immunization Practices

October 24, 2024

3 Terms of Reference

- GSK pentavalent (MenABCWY) vaccine
 - Prescription Drug User Fee Act date for regulatory decision:
 - February 14, 2025
- MenB-4C (Bexsero) FDA interval and dosing change
- Revisiting the adolescent meningococcal vaccine schedule

3 Terms of Reference

- GSK pentavalent (MenABCWY) vaccine **Vote Feb 2025**
 - Prescription Drug User Fee Act date for regulatory decision:
 - February 14, 2025
- MenB-4C (Bexsero) FDA interval and dosing change **Vote Oct 2024**
- Revisiting the adolescent meningococcal vaccine schedule **Vote 2025**


GSK Pentavalent (MenABCWY) Vaccine

- Today:
 - Cost-effectiveness
 - Evidence to Recommendations Framework (EtR)
 - Includes GRADE

MenB-4C (Bexsero) FDA Interval and Dosing Change


- Today:
 - Abridged Evidence to Recommendations (EtR) Framework
 - Cost-effectiveness and GRADE *not* indicated
 - Work Group considerations
 - **Vote**

Meningococcal Disease Incidence – United States, 1996–2023*



Abbreviations: MenACWY vaccine = quadrivalent (serogroups A, C, W, and Y) meningococcal conjugate vaccine; MenB vaccine = serogroup B meningococcal vaccine
Source: 1996–2023 NNDSS Data. *2023 NNDSS data are preliminary.


Trends in Meningococcal Disease Incidence by Serogroup – United States, 2006–2023*



Source: NNDSS data with additional serogroup data from Active Bacterial Core surveillance (ABCs) and state health departments


*2023 data are preliminary

Average Annual Meningococcal Disease Incidence by Age Group and Serogroup—United States, 2012–2021



Source: NNDSS data with additional serogroup data from ABCs and state health departments

Average Annual Meningococcal Disease Incidence by Age Group and Serogroup—United States, 2022–2023*



Source: NNDSS data with additional serogroup data from ABCs and state health departments

*2023 NNDSS data are preliminary.

ACIP Meningococcal Vaccines Work Group

- **ACIP Members on the WG**

- Jamie Loehr (Chair)
- Wilbur Chen
- Charlotte Moser

- **Ex Officio WG Members**

- Margaret Bash (FDA)
- Matthew Clark (IHS)
- Xin-Xing Gu (NIH)

- **WG Liaisons and Consultants**

- Amra Resic (AAFP)
- Mary Healy (AAP)
- Barb Fluty (ACHA)
- Karyn Lyons (AIM)
- Paul Cieslak (CSTE)
- Kathy Hsu (IDSA)
- Pamela Doyon-Plourde (NACI)
- Jeff Goad (NFID)
- Jessica Cataldi (PIDS)
- Amy Middleman (SAHM)
- Kathy Poehling (Wake Forest)
- Lynn Bahta (Minnesota Department of Health)
- David Stephens (Emory)

- **GRADE/EtR Support**

- Doug Campos-Outcalt (Arizona)
- Rebecca Morgan (Case Western Reserve)

- **CDC Contributors**

- Sarah Schillie (DBD/NCIRD) – Meningococcal Lead
- Jennifer Collins (DBD/NCIRD) – Hib Lead
- Lucy McNamara (DBD/NCIRD)
- Avnika Amin (DBD/NCIRD)
- LeAnne Fox (DBD/NCIRD)
- Susan Hariri (DBD/NCIRD)
- Amy Rubis (DBD/NCIRD)
- Jennie Thomas (DBD/NCIRD)
- Noele Nelson (DBD/NCIRD)
- Alison Albert (DBD/NCIRD)
- Shelby Miller (DBD/NCIRD)
- Michelle Hughes (DBD/NCIRD)
- Madhura Vachon (DBD/NCIRD)
- Gabrielle Cooper (DBD/NCIRD)
- Xiaoyu Dong (ISD/NCIRD)
- Andrew Leidner (ISD/NCIRD)
- Ismael Ortega-Sanchez (CORVD/NCIRD)
- Marc Fischer (DIDRI/NCEZID)
- Jonathan Duffy (DHQP/NCEZID)
- Pedro Moro (DHQP/NCEZID)
- Tanya Myers (DHQP/NCEZID)
- Leslie Lee (OD/NCIRD)
- Manisha (Mo) Patel (OD/NCIRD)
- Jessica MacNeil (ACIP Secretariat)
- Hannah Rosenblum (ACIP Secretariat)
- Melinda Wharton (ACIP Secretariat)